Nanosyrinx Ltd

Nanosyrinx Ltd from Coventry UK: a small, active company founded six years ago, employs twelve people, and holds £2,041,372 in assets. It’s a real address, managed by seven directors, but surprisingly, there are no listed owners. The company regularly imports miscellaneous chemical products, with activity spanning ten months, the last operation occurring in August 2024.

Nanosyrinx Ltd operates in the biotechnology industries, specifically focused on research and experimental development. Their website highlights a novel platform technology for targeted intracellular delivery of biologic molecules, aiming to unlock therapeutic opportunities within cells. They’re actively recruiting, and recently announced appointments to strengthen their research and development team, alongside a £10 million financing round led by BGF, Octopus Ventures, and M Ventures. The company’s website also mentions a collaboration with Eli Lilly and Company.

Financially, Nanosyrinx Ltd shows a mixed picture. Cash bank holdings increased by a healthy 44% to £2 million, and fixed assets grew by 83% to £410,000. However, accumulated amortisation and depreciation have also increased significantly, totaling £7,400 and £91,000 respectively. Creditors have risen sharply by 190% to £210,000, and net current assets and liabilities have increased by 28% to £1.8 million. While the company’s employee numbers have increased by 42% to seventeen, trade debtors have decreased by 43% to £72,000. It’s a small company, meeting two of three conditions for classification (turnover under £10.2 million, assets under £5.1 million, fewer than 50 employees). The lack of an auditor is expected given its size, and the financial statements are unaudited.

Registered in England/Wales under the registration number 11595354, with a registered address at CV4 7EZ, England, Coventry, West Midlands, Unit 23b, The Venture Centre Sir William Lyons Road, University Of Warwick Science Park.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.